MRK$148.69

Merck does not benefit from meaningful network effects in the way software, payments, or marketplaces do. Prescribing a Merck oncology drug does not become more valuable because more patients use it, and a hospital’s adoption of one product does not create a strong self-reinforcing ecosystem around the next product. There are some indirect reinforcement loops from guideline inclusion, physician familiarity, and companion diagnostics, but those are better described as commercial momentum than true network effects. Even in oncology, treatment decisions remain based on clinical evidence, reimbursement, and safety rather than peer participation. That keeps this pillar weak, with little evidence that Merck’s customer base makes the franchise harder to displace over time.

Switching costs are meaningful in several of Merck’s franchises, especially in oncology and vaccines, where physicians, hospitals, and payers build treatment pathways around approved products and long-standing safety data. Once a patient is stabilized on a regimen, or a hospital protocol is embedded in formularies and ordering systems, changing therapy can require clinical justification, payer approval, and retraining. That said, these costs are not absolute; if a rival drug demonstrates better efficacy, safety, convenience, or economics, switching can happen relatively quickly. The company’s strongest switching friction comes from established treatment protocols, not from technical integration or contractual lock-in. This supports a solid but not extreme advantage.

Merck’s moat is strongest in intangible assets. The company relies on patents, biologic exclusivity, FDA-approved indications, clinical data, and brand trust built through decades of successful launches. Keytruda is the clearest example: its oncology data package, label breadth, and physician familiarity are difficult to replicate even before exclusivity expires. Gardasil also benefits from strong brand recognition and a highly defensible clinical profile. Merck’s animal health and hospital products likewise depend on regulatory approvals and manufacturing know-how that are not easily copied. The limitation is that these advantages are time-bound, and patent cliffs are real. Still, the breadth of Merck’s protected portfolio keeps this pillar very strong.

Merck has some cost advantages from scale, but they are modest relative to the size of the business. Large-volume manufacturing of vaccines, biologics, and animal health products allows the company to spread fixed costs across a broad base, and its global supply chain is more efficient than that of smaller biotech firms. Merck also benefits from established R&D capabilities and a history of late-stage development execution. However, pharmaceutical pricing is not primarily determined by unit cost, and competitors with enough capital can often match manufacturing economics over time. In practice, Merck’s advantage is better described as operational efficiency and scale discipline than a structurally lower-cost position versus the field.

Merck operates in markets with high barriers to entry, but not in a natural-monopoly structure. Drug development requires enormous capital, clinical expertise, manufacturing quality, and regulatory success, which reduces the number of serious competitors in any given therapeutic area. In some categories, such as HPV vaccines or checkpoint oncology, only a few large players matter. Yet across the broader pharmaceutical industry, Merck still faces multiple well-funded rivals from Bristol Myers, Roche, AstraZeneca, Novartis, Pfizer, GSK, and others. That means the market is competitive rather than naturally exclusive. Merck benefits from efficient scale in selected niches, but the company does not control a market structure that blocks entry in a durable, monopoly-like way.